Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Fig. 3

The comparison of outcomes between R-based chemoimmunotherapy and chemotherapy groups in 41 FL patients. a Patients with R-based chemoimmunotherapy had superior PFS than patients with chemotherapy (not reached vs. 47 months, P = 0.013). b Patients with R-based chemoimmunotherapy had superior OS than patients with chemotherapy (not reached vs. 54 months, P = 0.001)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us